ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part four of her interview, Stella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, reframes what "leaner" really means in practice, not cutting corners but deploying fractional teams and strategic partners to reach inflection points faster on limited capital. The model depends less on headcount reduction and more on alignment between startup capability and outsourced expertise at each development phase.
• The FDA outlined structural barriers slowing Phase I trials in the US, where timelines extend to 2 years compared to 9 months in China, delaying patient access and pushing early-stage capital overseas. Acting CBER director Karim Mikhail detailed the Expedited IND Pilot, which enlists qualified research institutions to provide iterative discipline-specific guidance during IND preparation and tests rolling submission of completed components rather than waiting for full packages.
• The FDA granted accelerated approval to Tudriqev plus nivolumab for unresectable advanced cutaneous melanoma progressing on anti-PD-1 therapy, addressing a high-unmet-need population where over 50% progress within six months and median overall survival after progression is under one year. The Ignyte trial showed an objective response rate of 24.2% and median duration of response of 14.1 months in patients required to have at least one non-injected lesion.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.